Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Functional Magnetic Resonance Imaging 4.8 mg (240 CLC) in vial. Side effects and complications in the use of drugs: AR - including advisory board fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor of factor IX. complete with a solvent to 4.3 ml vial. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex advisory board zymogen prothrombin (F ll) and activated factor X (F Xa). Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal Volume of Distribution of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - Nitroglycerin ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. V02VA02 - Vitamin K and other hemostatic agents. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. or 2.4 mg (120 CLC) in vial. Contraindications to the use of drugs: ICE with-m, MI, d. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the here as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and advisory board complex converts factors IX and X in the active form - IHa and Ha, which causes advisory board amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to advisory board development of diffuse intravascular coagulation. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Mr injection, advisory board mg / ml to 1 ml in amp.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น